SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?


To: HardToFind who wrote (10057)4/11/2018 5:55:29 AM
From: old 'n cranky  Read Replies (1) | Respond to of 12873
 
"I think 50% of the first Phase I (human toxicity) would not have to be repeated for the second or third indications."
"Once Phase I is done for one indication, risk has been reduced and the cost has dropped for the next two...."

Appreciate the explanation.

"I don't know if it's orchestrated or not"
I don't know either, but a number of years worth of evidence support my opinion that it is.